Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2544–2546. doi: 10.1128/aac.41.11.2544

Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins.

T Deguchi 1, M Yasuda 1, KawamuraT 1, M Nakano 1, S Ozeki 1, E Kanematsu 1, Y Nishino 1, Y Kawada 1
PMCID: PMC164159  PMID: 9371364

Abstract

MICs of DU-6859a, a novel fluoroquinolone, for 18 Klebsiella pneumoniae isolates and 21 Enterobacter cloacae isolates with altered GyrA or altered GyrA and ParC ranged from < or =0.025 to 6.25 microg/ml and from 0.1 to 3.13 microg/ml, respectively. Based on the MICs at which 90% of the isolates were inhibited for these strains of K. pneumoniae and E. cloacae, DU-6859a exhibited 16- to 256-fold-greater activity than currently available fluoroquinolones.

Full Text

The Full Text of this article is available as a PDF (146.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belland R. J., Morrison S. G., Ison C., Huang W. M. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol. 1994 Oct;14(2):371–380. doi: 10.1111/j.1365-2958.1994.tb01297.x. [DOI] [PubMed] [Google Scholar]
  2. Deguchi T., Fukuoka A., Yasuda M., Nakano M., Ozeki S., Kanematsu E., Nishino Y., Ishihara S., Ban Y., Kawada Y. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1997 Mar;41(3):699–701. doi: 10.1128/aac.41.3.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Deguchi T., Yasuda M., Nakano M., Kanematsu E., Ozeki S., Ishihara S., Saito I., Kawada Y. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV. J Antimicrob Chemother. 1997 Feb;39(2):247–249. doi: 10.1093/jac/39.2.247. [DOI] [PubMed] [Google Scholar]
  4. Deguchi T., Yasuda M., Nakano M., Ozeki S., Ezaki T., Saito I., Kawada Y. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother. 1996 Apr;40(4):1020–1023. doi: 10.1128/aac.40.4.1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Georgiou M., Muñoz R., Román F., Cantón R., Gómez-Lus R., Campos J., De La Campa A. G. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother. 1996 Jul;40(7):1741–1744. doi: 10.1128/aac.40.7.1741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 1996 Apr;40(4):879–885. doi: 10.1128/aac.40.4.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Heisig P., Schedletzky H., Falkenstein-Paul H. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 1993 Apr;37(4):696–701. doi: 10.1128/aac.37.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Khodursky A. B., Zechiedrich E. L., Cozzarelli N. R. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801–11805. doi: 10.1073/pnas.92.25.11801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kitamura A., Hoshino K., Kimura Y., Hayakawa I., Sato K. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995 Jul;39(7):1467–1471. doi: 10.1128/aac.39.7.1467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kumagai Y., Kato J. I., Hoshino K., Akasaka T., Sato K., Ikeda H. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother. 1996 Mar;40(3):710–714. doi: 10.1128/aac.40.3.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nakashima M., Uematsu T., Kosuge K., Umemura K., Hakusui H., Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1995 Jan;39(1):170–174. doi: 10.1128/aac.39.1.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992 Jul;36(7):1491–1498. doi: 10.1128/aac.36.7.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tanaka M., Hoshino K., Hohmura M., Ishida H., Kitamura A., Sato K., Hayakawa I., Nishino T. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method. J Antimicrob Chemother. 1996 Jun;37(6):1091–1102. doi: 10.1093/jac/37.6.1091. [DOI] [PubMed] [Google Scholar]
  14. Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271–1272. doi: 10.1128/aac.34.6.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yoshida H., Nakamura M., Bogaki M., Ito H., Kojima T., Hattori H., Nakamura S. Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother. 1993 Apr;37(4):839–845. doi: 10.1128/aac.37.4.839. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES